6. Cardiovascular Considerations
Long-term metformin use has been associated with beneficial effects on certain cardiovascular risk markers, including improvements in lipid profiles and blood pressure in some patients. Large clinical studies suggest metformin may reduce cardiovascular events in people with type 2 diabetes compared to some other glucose-lowering drugs.
However, individual cardiovascular risk depends on multiple factors such as age, smoking status, cholesterol levels, and blood pressure control. Metformin should be viewed as one component of a broader cardiovascular risk management strategy.
7. Alcohol Interaction Risks
Consuming alcohol while taking metformin requires caution because excessive intake can increase the risk of lactic acidosis, a rare but serious complication. Alcohol affects liver metabolism and can exacerbate conditions that predispose to this risk.
Moderate alcohol consumption may be permissible for some individuals, but it is critical to discuss personal drinking habits openly with your healthcare provider. Avoid binge drinking and seek guidance on safe limits tailored to your health status.
8. Kidney Function Monitoring
Metformin is eliminated primarily by the kidneys, so kidney function significantly affects dosing and safety. Patients with reduced kidney function may accumulate metformin, increasing the risk of adverse effects.
Regular monitoring of estimated glomerular filtration rate (eGFR) is recommended before starting metformin and periodically thereafter. Dose adjustments or alternative medications may be necessary if kidney function declines.
Important: Never adjust or stop metformin without consulting your healthcare provider.
